Angela Mauro,Donato Rigante,Rolando Cimaz
Angela Mauro
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The improvement of knowledge about the pathogenetic mechanisms of JIA and advances in the understanding of pathways linking inflammation and auto...
Christopher J Smart,Kamran I Malik
Christopher J Smart
Postoperative ileus (POI) is an impairment of coordinated gastrointestinal (GI) motility that develops as a consequence of abdominal surgery and is a major factor contributing to patient morbidity and prolonged hospitalisation. Despite the ...
Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials [0.03%]
从动物研究到二期试验：探究性肺鳞状细胞癌疗法
Elaine Shum,Feng Wang,Salem Kim et al.
Elaine Shum et al.
It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas c...
Drugs in clinical development for the treatment of amyotrophic lateral sclerosis [0.03%]
临床开发用于治疗肌萎缩侧索硬化的药物
Ana Martinez,Maria Del Valle Palomo Ruiz,Daniel I Perez et al.
Ana Martinez et al.
Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron progressive disorder for which no treatment exists to date. However, there are other investigational drugs and therapies currently under clinical development may offer hope in the ...
Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study [0.03%]
盐酸和戊聚醇治疗皮肤T细胞淋巴瘤的疗效研究——II期临床试验
Jose Ramiro Espinoza-Zamora,Juan Labardini-Méndez,Alejandro Sosa-Espinoza et al.
Jose Ramiro Espinoza-Zamora et al.
Objectives: To evaluate the activity and safety of hydralazine and valproate (Transkrip) in cutaneous T-cell lymphoma (CTCL). Methods: ...
Novel avenues for treating diabetic nephropathy: new investigational drugs [0.03%]
糖尿病肾病的新型疗法：新的 Investigational Drugs
Viviana Lacava,Vincenzo Pellicanò,Carmen Ferrajolo et al.
Viviana Lacava et al.
At present, treatment of diabetic kidney disease (DKD) is still mainly based on drugs acting on glycemic and blood pressure control, as there is no validated therapy able to halt the progression of renal failure. Because of the high inciden...
Heat shock protein antagonists in early stage clinical trials for NSCLC [0.03%]
用于治疗NSCLC的热休克蛋白拮抗剂早期临床试验
Lizza E L Hendriks,Anne-Marie C Dingemans
Lizza E L Hendriks
Cancer cells have a higher need of chaperones than normal cells to prevent the toxic effects of intracellular protein misfolding and aggregation. Heat shock proteins (Hsps) belong to these chaperones; they are classified into families accor...
Fabio Barra,Domenica Lorusso,Umberto Leone Roberti Maggiore et al.
Fabio Barra et al.
Cervical cancer (CC) is currently the fourth most common malignant disease of women worldwide. Although the incidence and the mortality rates have been decreasing with screening detection and new treatment strategies, a significant number o...
Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer [0.03%]
乳腺癌表皮生长因子受体靶向治疗的早期临床研究
Naoko Matsuda,Bora Lim,Xiaoping Wang et al.
Naoko Matsuda et al.
Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in ...
Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies [0.03%]
胃肠道间质瘤的临床开发格局：从针对替代通路的新型药物到重新审视非靶向治疗
Kamalesh K Sankhala
Kamalesh K Sankhala
Activating mutations in the genes encoding the tyrosine receptor kinases KIT and platelet-derived growth factor receptor occur in 85%-90% of patients with gastrointestinal stromal tumors (GIST). Although imatinib and other tyrosine kinase i...